Results 41 to 50 of about 728,357 (259)

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine [PDF]

, 2004
Background: Calcitonin gene–related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks.
Diener, H.-C., Goadsby, P.J., Hall, D., Husstedt, I.G., Lesko, L.M., Meier, U., Olesen, J., Pollentier, S.   +7 more
core   +1 more source

Patient Perceptions of Medication Therapy for Prevention of Posttraumatic Osteoarthritis Following Anterior Cruciate Ligament Injury: A Qualitative Content Analysis

Arthritis Care &Research, EarlyView.
Objective Posttraumatic osteoarthritis (PTOA) accounts for nearly 12% of osteoarthritis incidences and often occurs after anterior cruciate ligament (ACL) tear. Ensuring the uptake of preventive treatments for PTOA requires that investigators and clinicians understand factors influencing patients to seek preventive therapies.
Lily M. Waddell, Donald P. Mitchener, Kelly C. Frier, Morgan H. Jones, Elena Losina, Nick Bansback, Liana Fraenkel, Jason S. Kim, Jeffrey N. Katz, Faith Selzer, Adam Easterbrook   +10 more
wiley   +1 more source

Rolofylline, an adenosine A1−receptor antagonist, in acute heart failure [PDF]

, 2010
Background: Worsening renal function, which is associated with adverse outcomes, often develops in patients with acute heart failure. Experimental and clinical studies suggest that counterregulatory responses mediated by adenosine may be involved. We
Bloomfield, Daniel M., Cleland, John G.F., Cotter, Gad, DeLucca, Paul, Dittrich, Howard C., Givertz, Michael M., Mansoor, George A., Massie, Barry M., Metra, Marco, O'Connor, Christopher M., Ponikowski, Piotr, Salerno, Christina M., Teerlink, John R., Voors, Adriaan, Weatherley, Beth Davison   +14 more
core   +1 more source

Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis

Arthritis Care &Research, EarlyView.
Objective We aimed to assess differences in baseline characteristics, efficacy, and safety of advanced therapies between male and female patients with axial spondyloarthritis (axSpA) in randomized controlled trials (RCTs). Methods We conducted a systematic literature search for RCTs assessing the efficacy of advanced therapies in patients with axSpA ...
Angel Gao, Jordi Pardo Pardo, Steven Dang, Lianne S. Gensler, Philip Mease, Lihi Eder   +5 more
wiley   +1 more source

Implementing placebo [PDF]

BMJ, 2008
Pittrof and Rubinstein make the important point that the “placebo effect” is actually an effect—people often do get better on placebo.1 However, most, if not all, of the evidence for placebo effects comes from studies where patients expected to have a reasonable chance (generally 0.5) of receiving the active treatment.
openaire   +3 more sources

Placebo Effect Sizes in Clinical Trials of Knee Osteoarthritis Using Intra‐Articular Injections of Biologic Agents

Arthritis Care &Research, EarlyView.
Objective Patients with knee osteoarthritis rely on symptomatic treatments, in which up to 75% of the pain reduction can be attributed to the placebo effect. This effect may vary based on treatment type (eg, biologics vs nonbiologic injection) and route of administration (eg, intra‐articular vs topical vs oral).
Johanna M. Borst, Severin Ruoss, Ian Palmer, Trevor Smith, Kenneth Kalunian, Samuel R. Ward   +5 more
wiley   +1 more source

Racial Differences in the Effect of Granulocyte Macrophage Colony-Stimulating Factor on Improved Walking Distance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. [PDF]

, 2019
Background The effects of race on response to medical therapy in people with peripheral artery disease ( PAD ) are unknown. Methods and Results In the PROPEL (Progenitor Cell Release Plus Exercise to Improve Functional Performance in PAD) Trial, PAD ...
Criqui, Michael H, Domanchuk, Kathryn, Ferrucci, Luigi, Guralnik, Jack M, Kibbe, Melina R, Li, Lingyu, McDermott, Mary M, Polonsky, Tamar S, Stein, James, Taylor, Doris A, Tian, Lu, Zhao, Lihui   +11 more
core   +1 more source

Metabolic Consequences of Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry, Emily Sheng, Joshua F. Baker   +2 more
wiley   +1 more source

Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder:results from a randomized, controlled trial [PDF]

, 2013
Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD). This randomized placebo-controlled trial of an optimized daily dose of LDX (30, 50 or 70 mg) was conducted in
Alessandro Zuddas, CK Conners, D Coghill, David R. Coghill, DE May, E Taylor, FA Lopez, G Polanczyk, Isabel Hernández Otero, J Biederman, J Biederman, J Biederman, J Cohen, J Elia, J Ermer, KP Garnock-Jones, LA Adler, Liza A. Squires, M Pennick, M Wolraich, Michel Lecendreux, RA Barkley, Ralf W. Dittmann, Ralph Bloomfield, Richard Civil, RL Findling, RL Findling, S Pliszka, SB Wigal, SW Boellner, T Banaschewski, T Wigal, Tobias Banaschewski, V Simon   +33 more
core   +2 more sources

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun, Lingling Cui, Robert Terkeltaub, Ying Chen, Xinde Li, Xiaoyu Cheng, Tian Liu, Nicola Dalbeth, Changgui Li   +8 more
wiley   +1 more source